^
Association details:
| Biomarker: | EGFR exon 19 deletion |
|---|---|
| Cancer: | Small Cell Lung Cancer |
| Drug: | gefitinib (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Excerpt:
IRESSA is a tyrosine kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.
Source:
Title:
Evaluation of efficacy of gefitinib drug in patients with non-small cell tumors with EGFR and TP53 gene mutation Valutazione di efficacia del farmaco gefitinib in pazienti affetti da tumore non a piccole cellule con mutazione del gene EGFR e TP53
Excerpt:
...Locally identified EGFR exon 19 deletion or exon 21 p.L858R. ...
Trial ID:
Source:
Title:
Extensive-Stage Small Cell Carcinoma Transformation From EGFR Del19-Mutant Lung Adenocarcinoma on Gefitinib at the Twelfth-Year Follow-Up Case Report
Published date:
03/18/2021
Excerpt:
EGFR mutation analysis using matrix-assisted-laser-desorption-ionization time-of-flight mass spectrometry (MALDI-TOF MS) for SCLC identified the same deletion in exon 19 (Figure 2D). The patient continued to receive treatment with gefitinib. The justification for continuing gefitinib was the presence of the activating EGFR mutation....The serial whole-body bone scans demonstrated stabilized disease with neither cortical destruction nor pathological fractures over the years....As of February 22, 2021, she has an excellent performance status...
DOI:
10.3389/fonc.2021.564799
